GO
Loading...

Enter multiple symbols separated by commas

Stocks AstraZeneca PLC

More

  • Brilinta? Brintellix? FDA warns of drug name mix-ups Thursday, 30 Jul 2015 | 1:28 PM ET

    NEW YORK— The Food and Drug Administration said Thursday that some doctors and pharmacies are getting confused by the similar names of an antidepressant and a blood-thinning medicine. The FDA says it's not aware of any patients who took the wrong drug, but the agency says it has received 50 reports of medication errors, including cases where doctors prescribed...

  • Drug firm AstraZeneca reports slide in earnings Thursday, 30 Jul 2015 | 4:02 AM ET

    LONDON— Anglo-Swedish drug firm AstraZeneca says second-quarter net income fell 12 percent to $697 million as competition from generic drug companies reduced sales. CEO Pascal Soriot says the company made "good progress" in the period, with cost reductions supporting investment in science. Soriot also highlighted progress in the company's oncology...

  • LONDON, July 30- AstraZeneca revenue fell by a smaller-than-expected 7 percent in the second quarter, as income from spinning off assets offset generic competition to older medicines and a strong dollar. Chief Executive Pascal Soriot, who fended off a $118 billion takeover attempt by Pfizer last year, is banking on a promising pipeline of new drugs-...

  • NEW YORK— French drugmaker Sanofi said Monday it will pay up to $300 million to buy a thyroid cancer drug from British competitor AstraZeneca. Sanofi's Genzyme unit will pay $165 million for Caprelsa, and it agreed to make another $135 million in milestone payments based on regulatory development and sales targets. U.S.-traded shares of Sanofi fell 43 cents to...

  • The operator from northwest Spain was bought by Zegona, formed by Eamonn O'Hare and Robert Samuelson, who helped build up and then sell Virgin Media in 2013.. The deal is the fourth big telecoms deal in Spain in the last 18 months, after Vodafone bought Ono, Orange snapped up Jazztel and Euskaltel last week agreed an offer for R Cable. It will fund the acquisition with...

  • Zegona buys Spain's Telecable for 640 mln euros Monday, 27 Jul 2015 | 2:39 AM ET

    LONDON, July 27- Zegona, the company set up by the former Virgin Media finance director Eamonn O'Hare, said on Monday it had bought Spanish cable operator Telecable for an enterprise value of 640 million euros. Zegona, set up to buy and run businesses in the European technology, media and telecoms sector, said it would fund the acquisition with a combination of 251...

  • LONDON, July 24- AstraZeneca is dipping its toe in the biosimilars market, as a way to make future cancer drug cocktails more affordable, by linking with a Japanese group to develop a copy of Roche's blockbuster medicine Avastin. FKB-- itself a tie-up between Fujifilm and Kyowa Hakko Kirin-- commenced a Phase I clinical trial of its copy of Avastin, called FKB238, in...

  • July 20- Bristol-Myers Squibb Co said a late-stage trial of its drug, Opdivo, was stopped early after the immunotherapy was found to be effective in patients with the most common form of kidney cancer. The drug competes with Merck& Co's Keytruda. AstraZeneca Plc, Pfizer Inc and other drugmakers are also developing PD-1 inhibitors, or similar drugs known as PD-L1...

  • DUBLIN, July 16- Britain's Immunocore completed Europe's largest ever financing round by a private life sciences company on Thursday, raising $320 million from investors including Eli Lilly& Co, Malin and Woodford Investment Management. The investment by some of the healthcare sector's "most highly regarded international institutions" is another...

  • *Paulson expected to put pressure on Syngenta board. July 15- Hedge fund Paulson& Co has taken a stake in Syngenta AG and could push for the Swiss pesticide maker's board to accept a takeover offer from U.S. seed company Monsanto Co, people familiar with the matter said. Monsanto, the world's largest seed company, has made a $45 billion bid for Syngenta that the Swiss...

  • July 14- Celgene Corp said on Tuesday it would buy Receptos Inc for $7.2 billion in a move that will give the U.S. biotechnology company a potential multibillion-dollar drug in late stage development for inflammatory bowel disease and multiple sclerosis. The Receptos move comes just two weeks after Celgene said it would invest $1 billion in Juno Therapeutics...

  • July 13- The U.S. Food and Drug Administration approved AstraZeneca Plc's drug, Iressa, as a first-line treatment for a common form of lung cancer. The FDA said on Tuesday the approval was based on results from a trial of 106 patients with previously untreated non-small cell lung cancer. The National Cancer Institute estimates more than 158,000 will die from the...

  • July 13- The U.S. Food and Drug Administration has approved AstraZeneca Plc's drug, Iressa, as a first-line treatment for a common form of lung cancer. The drug was previously approved for use in non-small cell lung cancer patients only after they did not respond to chemotherapy. The FDA said on Tuesday the approval was based on results from a trial of 106 patients...

  • AstraZeneca divests gastrointestinal drug for $215 mln Thursday, 9 Jul 2015 | 3:07 AM ET

    LONDON, July 9- AstraZeneca struck a further "externalisation" deal on Thursday to help fill its short-term revenue gap by divesting its gastrointestinal drug Entocort for $215 million. The transaction is expected to complete in the second half of 2015 and AstraZeneca said it would reinforce its strategic focus on selected therapy areas, such as cancer,...

  • June 22- The U.S. Food and Drug Administration on Monday approved Medicines Co's blood clot preventer Cangrelor, which has faced multiple setbacks since it first entered late-stage studies close to a decade back. Medicines Co has funneled about $200 million into developing Cangrelor over the past decade, which included two unsuccessful trials and a pivotal...

  • Shares of the company, whose customers include AstraZeneca Plc, General Electric Co and Chevron Corp, rose about 8 percent in extended trading on Wednesday. Box raised its full-year forecast to $286 million- $290 million from $281 million- $285 million earlier. The company's main competitors include privately held Dropbox, Microsoft Corp's OneDrive, Citrix...

  • LONDON, June 10- AstraZeneca's chief medical officer and head of global late-stage drug development Briggs Morrison is to leave the company, creating a gap at the top of the group's research operations. A spokeswoman said on Wednesday Morrison was departing to become chief executive of an unlisted venture capital-backed drugmaker in the United States,...

  • LONDON, June 10- AstraZeneca's chief medical officer and head of global late-stage drug development Briggs Morrison is to leave the company, creating a gap at the top of the group's research operations. Morrison, who joined AstraZeneca from Pfizer in 2012, has played a central role in the British drugmaker's bid to turn around its portfolio.

  • M&A: Dealmaking like 2007 all over again? Wednesday, 3 Jun 2015 | 7:29 AM ET

    Mergers and acquisitions are close to pre-financial crisis levels for the first time in 2015, as companies search for deals again.

  • June 2- AstraZeneca Plc would consider acquiring a developer of a new type of cancer therapy aimed at supercharging the body's immune response, Bloomberg quoted Chief Executive Pascal Soriot as saying on Tuesday. An earlier version of the Bloomberg article quoted Soriot as saying that AstraZeneca would consider buying a company such as Juno Therapeutics...